Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Isis Earns Biogen Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Isis Earns Biogen Milestone

Advances Phase III Evaluation of SMNRx

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals, Inc. has earned a $9 million milestone payment from Biogen Idec related to advancing the Phase III study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA). 
 
The ENDEAR study will evaluate the efficacy and safety of a 12 mg dose of ISIS-SMNRx with a primary endpoint of survival or time to permanent ventilation in approximately 110 infants diagnosed with SMA. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics